Dbv Technologies S.A.

Dbv Technologies S.A. is a biopharmaceutical company engaged in the research and development of innovative immunotherapy treatments. Its primary purpose is to create safe and effective therapies for severe food allergies, with a focus on revolutionizing the way these conditions are treated. The company is renowned for its proprietary technology, Viaskin, an epicutaneous delivery platform designed to deliver biologically active compounds directly through the skin without the need for injection. This unique approach targets patients suffering from peanut allergies and is extending its application to milk and egg allergies. As a key player in the biopharmaceutical sector, Dbv Technologies actively influences advancements in allergy treatment methodologies globally. With its headquarters in France and a wide-reaching impact, the company holds a significant position in the market, addressing a crucial area of unmet medical needs. By delivering potentially transformative therapies, Dbv Technologies contributes to enhancing patients' quality of life and advancing the field of allergy treatment.